The popularity of Novo Nordisk’s (NVO) weight-loss drug, Wegovy, has already catapulted its stock to become Europe’s most valuable company, as measured by market capitalization. Wegovy is a GLP-1 drug. Glucagon-like peptide-1 (GLP-1) agonists are a class of drugs used to treat type 2 diabetes and obesity. They mimic the action of GLP-1, a hormone released by the stomach after eating that signals the pancreas to produce more insulin and keep blood sugar levels normal. There is much more to come for the company and its GLP-1 drugs. One reason for this is the recent announcement that Wegovy “has …